Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TIGER: Vitrectomy, subretinal tissue plasminogen activator and intravitreal gas vs anti-VEGF monotherapy for submacular haemorrhage secondary to exudative age-related macular degeneration
2020-004917-10Phase 3Active
- Sponsor
- King's College London
- Start
- Nov 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of tissue-plasminogen activator in exudative macular degeneration (2 arms), sponsored by King's College London. Primary endpoint: Gain of at least 10 ETDRS letters in BCVA at month 12 in the study eye. Started Nov 2022; status: active.
02
Drugs
tissue-plasminogen activator
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on 2020-004917-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004917-10.